Proteomics International Laboratories Ltd (ASX:PIQ)
Australia · Delayed Price · Currency is AUD 0.4900
-0.0800 (-14.04%)
Jan 30, 2026, 12:53 PM AEST
ASX:PIQ Revenue
In the fiscal year ending June 30, 2025, Proteomics International Laboratories had annual revenue of 3.31M AUD with 1.34% growth. Proteomics International Laboratories had revenue of 2.48M in the half year ending June 30, 2025, with 2.53% growth.
Revenue
3.31M
Revenue Growth
+1.34%
P/S Ratio
28.41
Revenue / Employee
n/a
Employees
n/a
Market Cap
94.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.31M | 43.87K | 1.34% |
| Jun 30, 2024 | 3.27M | 87.53K | 2.75% |
| Jun 30, 2023 | 3.18M | -249.17K | -7.26% |
| Jun 30, 2022 | 3.43M | 694.47K | 25.38% |
| Jun 30, 2021 | 2.74M | 6.89K | 0.25% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Starpharma Holdings | 5.85M |
| Alterity Therapeutics | 5.44M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Arovella Therapeutics | 3.44M |
| Cynata Therapeutics | 1.89M |